Dendreon (DNDN) Cash Flow Statement

Click line-items for a historical chart and %

Net loss	-73.72M
Depreciation and amortization expense	18.4M
Non-cash stock-based compensation expense	1.2M
Loss on valuation of warrant liability
Amortization of securities discount and premium	860K
Amortization of convertible notes discount and debt issuance costs	22.87M
Other
Trade accounts receivable	13.97M
Inventory	-5.96M
Prepaid antigen costs
Prepaid expenses and other assets	-837K
Accounts payable	2.22M
Accrued liabilities and compensation	-11.01M
Net cash used in operating activities
Maturities and sales of investments	55.7M
Purchases of investments	-8.03M
Purchases of property and equipment	-1.07M
Net cash used in investing activities
Net proceeds from issuance of convertible debt
Proceeds from exercise of warrant
Payments on facility lease obligations	-517K
Payments on capital lease obligations	-1.99M
Proceeds from release of security deposits	225K
Payments on letters of credit
Issuance of common stock under Employee Stock Purchase Plan	397K
Net proceeds from exercise of stock options and other
Net cash provided by financing activities
Net increase (decrease) in cash and cash equivalents	-38.59M
Cash and cash equivalents at beginning of period	92.53M
Cash and cash equivalents at end of period	53.94M
Cash paid during the period for interest	22.14M
Assets acquired under facility and capital leases
Increase in asset retirement obligation
Exercise of warrants

Entities mentioned with DNDN

View All Entities